Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 4

2(28.6%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(3)

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04578938Phase 4Active Not Recruiting

Ketamine + Cognitive Training for Suicidality in the Medical Setting

Role: lead

NCT04580043Not ApplicableCompleted

Theta Burst Stimulation Plus Habit Override Training for Compulsive Behaviors

Role: lead

NCT06400121Phase 2Recruiting

Apimostinel + Automated Neurocognitive Training for Depression

Role: lead

NCT05168735Phase 1Completed

Ketamine + Mindfulness for Depression

Role: lead

NCT04916548Phase 1Completed

Repeated Neurocognitive Measurements in Depressed Patients

Role: lead

NCT04154150Phase 4Terminated

Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot

Role: lead

NCT03237286Phase 1Completed

Intravenous Ketamine Plus Neurocognitive Training for Depression

Role: lead

All 7 trials loaded